Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRTP-50X
- Development stage
- Preclinical
- Lead developer
- CellinCells
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Administration
- Injectable
01
Overview
TRTP-50X is an organoid-based muscle regenerative cell therapy being developed by CellinCells. It is derived from the company's Tissue Re-modeling Technology Platform (TRTP) and is designed to promote the regeneration of muscle tissue. The therapy is currently in preclinical development (MoA and CMC stages) for the treatment of sarcopenia and diabetic ulcers. By utilizing organoid technology, TRTP-50X aims to provide a more complex and functional cellular structure for tissue repair compared to traditional single-cell therapies.
Beyond the preview
Go deeper on TRTP-50X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRTP-50X.